Compare · AORT vs MDLN
AORT vs MDLN
Side-by-side comparison of Artivion Inc. (AORT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AORT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.51B, about 56.9x AORT ($904.6M).
- MDLN has been more active in the news (18 items in the past 4 weeks vs 4 for AORT).
- MDLN has more recent analyst coverage (25 ratings vs 9 for AORT).
- Company
- Artivion Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $904.6M
- $51.51B
- 1M return
- -
- +6.43%
- 1Y return
- -
- -7.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 18
- Recent ratings
- 9
- 25
Artivion Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Latest AORT
- SEC Form 10-Q filed by Artivion Inc.
- Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Artivion Reports Third Quarter 2026 Financial Results
- Artivion to Participate in Upcoming Investor Conferences
- Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
- Jefferies initiated coverage on Artivion with a new price target
- SVP, Regulatory and Quality Green Andrew M sold $286,656 worth of shares (11,480 units at $24.97), decreasing direct ownership by 22% to 40,160 units (SEC Form 4)
- SVP, Regulatory and Quality Green Andrew M sold $216,337 worth of shares (8,003 units at $27.03), decreasing direct ownership by 13% to 51,640 units (SEC Form 4)
- President & CEO Mackin James P sold $2,026,850 worth of shares (70,000 units at $28.95), decreasing direct ownership by 7% to 877,275 units (SEC Form 4)
- SVP, Regulatory and Quality Green Andrew M sold $17,586 worth of shares (616 units at $28.55), decreasing direct ownership by 1% to 59,643 units (SEC Form 4) to satisfy withholding tax
Latest MDLN
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers
- SEC Form EFFECT filed by Medline Inc.
- Medline Inc. announces pricing of secondary offering of Class A common stock
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock